Results 1 to 10 of about 1,054 (155)

Antagonism of CGRP Signaling by Rimegepant at Two Receptors [PDF]

Frontiers in Pharmacology, 2020
The “gepants” are a class of calcitonin gene-related peptide (CGRP) receptor antagonist molecules that have been developed for the prevention and treatment of migraine.
Christopher Walker, Andrew Siow, Debbie Hay   +2 more
exaly   +5 more sources

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade [PDF]

Advanced Science
Immune checkpoint blockade (ICB) shows limited clinical activity in TNBC, largely because immune‐cold tumors fail to sustain productive innate and adaptive anti‐tumor immunity within an immunosuppressive tumor microenvironment.
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
doaj   +3 more sources

A Phase 4, 24-Week, Open-Label Study to Evaluate the Safety and Tolerability of Once-Daily Dosing of 75 mg Rimegepant for Episodic Migraine Prevention [PDF]

Journal of Headache and Pain
Background Rimegepant is a small-molecule calcitonin gene-related peptide receptor antagonist approved in adults for acute treatment of migraine (with or without aura) and preventive treatment of episodic migraine (EM).
Robert J Fountaine, Terence Fullerton, Esther Straghan   +2 more
exaly   +3 more sources

Sex differences in the real-world use of rimegepant for short-term prevention of migraine in the United States [PDF]

Frontiers in Neurology
IntroductionShort-term prevention (STP) is a targeted treatment approach to minimize migraine attacks during specific, time-limited periods. Because migraine disproportionately affects women, this study evaluated sex-related differences in the context of
Teshamae Monteith, Jessica Cirillo, Karina Nakajima, Martine C. Maculaitis, Elizabeth McCaig, Nemin Chen, Lucy Abraham, Meghan Fajardo, Feng Dai, Jessica Ailani   +9 more
doaj   +2 more sources

Consistency of response to rimegepant for the acute treatment of migraine among real-world users – findings from the prospective observational CONFIDENCE study [PDF]

The Journal of Headache and Pain
Background Real-world data on the effectiveness of rimegepant for the acute treatment of migraine is limited, particularly regarding consistency of response over multiple attacks.
Richard B. Lipton, Lucy Abraham, Alexandre Urani, Giorgio Lambru, Peter J. Goadsby, Patricia Pozo-Rosich, Todd J. Schwedt, Kristina M. Fanning, Feng Dai, Karin Hygge Blakeman   +9 more
doaj   +2 more sources

Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials

Frontiers in Pharmacology, 2020
BackgroundAs one of the novel therapeutic drugs that targets Calcitonin gene-related peptide (CGRP), 75 mg rimegepant has been used for the acute management of migraine, which is one of the most common neurological diseases worldwide.
Zhouqing Chen, Zilan Wang, Zhong Wang
exaly   +3 more sources

Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine [PDF]

Frontiers in Neurology
BackgroundMigraine is a prevalent neurological condition, affecting approximately 14% of the population, and is a leading cause of disability. Conventional treatments may have limited efficacy and tolerability limitations in clinical practice. Rimegepant
Tong An, Xiwen Duan, Yixuan Liu, Jingqi Chuang, Jiamei Liu, Wenbo Shi, Zhixiang Liu   +6 more
doaj   +2 more sources

Efficacy and safety of rimegepant for acute and preventive treatment of migraine: a systematic review and meta-analysis of randomized controlled trials [PDF]

BMC Pharmacology and Toxicology
Background Migraine is a disabling neurological disorder with limited tolerability and cardiovascular limitations associated with traditional acute therapies such as triptans. Rimegepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist,
Dina M. Khodeer, Sally M. Abdelmonem, Komla Mawunyo Dossouvi, Mai Adawi, Eman Hamza, Dina A. Ali   +5 more
doaj   +2 more sources

Long-term safety and effectiveness of rimegepant for the preventive treatment of migraine in Japan: an open-label extension of a phase 3 study [PDF]

The Journal of Headache and Pain
Background The aim of the current analyses of a phase 3 randomized controlled trial conducted in Japan was to assess the long-term safety and effectiveness of rimegepant 75 mg, taken for up to 52 weeks, for the preventive treatment of migraine.
Yasuhiko Matsumori, Shigekazu Kitamura, Toshimasa Yamamoto, Tomofumi Ishikawa, Yuko Hoshino, Hiroki Yoshimatsu, Alexandra Thiry, Akio Arakawa, Terence Fullerton, Fumihiko Sakai, Takao Takeshima   +10 more
doaj   +2 more sources

Exposure Matching Using Population Pharmacokinetic Modeling and Simulation to Support Rimegepant Dose Selection for Pediatric Patients With Migraine [PDF]

Clinical and Translational Science
Rimegepant is a small molecule calcitonin gene‐related peptide receptor antagonist approved as a 75 mg orally disintegrating tablet for the acute treatment of migraine and the prevention of episodic migraine in adults.
Craig M. Comisar, Jim H. Hughes, Gary Mo, Rajinder Bhardwaj, Abhijeet Jakate, Chay Ngee Lim, Jing Liu   +6 more
doaj   +2 more sources